Compare SOLAI Limited (SLAI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs Tempus AI — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Tempus AI trades at $60.71 (market cap $11.67B). The key difference: Tempus AI is far larger — about 699.2× SOLAI Limited's market cap, and Tempus AI is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| SLAI | TEM | |
|---|---|---|
Market Cap | $16.69M | $11.67B |
Sector | Technology | Broad Market / Factor |
52-Week High | $21.63 | $103.25 |
52-Week Low | $2.74 | $41.55 |
Enterprise Value | $16.33M | $12.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
